CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Misra, Asish C.; Luker, Kathryn E.; Durmaz, Hakan; Luker, Gary D.; Lahann, Joerg

doi:10.1021/acs.biomac.5b00653

Cited by 35 publications

(29 citation statements)

References 35 publications

(93 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a small molecule ligand of CXCR4, Plerixafor (or AMD3100) was conjugated onto poly(lactide-co-glycolide) NPs, showed improved cellular uptake into MDA-MB-231 cells and enhanced siRNA-mediated gene silencing. [82] The folic acid-conjugated gold nanorods showed significantly enhanced uptake in cancer cells both in vitro and in vivo. [31] The results indicate that the folate receptor could also be used as a target for TNBC.…”

Section: Nanotherapeutics For Triple Negative Breast Cancermentioning

confidence: 99%

Nanoparticles for imaging and treatment of metastatic breast cancer

Wang

Zhang

2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction Metastatic breast cancer is one of the most devastating cancers that have no cure. Many therapeutic and diagnostic strategies have been extensively studied in the past decade. Among these strategies, cancer nanotechnology has emerged as a promising strategy in preclinical studies by enabling early identification of primary tumors and metastases, and by effective killing of cancer cells. Areas covered This review covers the recent progress made in targeting and imaging of metastatic breast cancer with nanoparticles, and treatment using nanoparticle-enabled chemo-, gene, photothermal- and radio-therapies. This review also discusses recent developments of nanoparticle-enabled stem cell therapy and immunotherapy. Expert opinion Nanotechnology is expected to play important roles in modern therapy for cancers, including metastatic breast cancer. Nanoparticles are able to target and visualize metastasis in various organs, and deliver therapeutic agents. Through targeting cancer stem cells, nanoparticles are able to treat resistant tumors with minimal toxicity to healthy tissues/organs. Nanoparticles are also able to activate immune cells to eliminate tumors. Owing to their multifunctional, controllable and trackable features, nanotechnology-based imaging and therapy could be a highly potent approach for future cancer research and treatment.

show abstract

Section: Nanotherapeutics For Triple Negative Breast Cancermentioning

confidence: 99%

Nanoparticles for imaging and treatment of metastatic breast cancer

Wang

Zhang

2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…[22][23][24][25][26] Additionally, within these systems, the incorporation of water-based and organicbased polymers, 25,[27][28][29] functional polymers for the creation of specific targeting and stealth patches on the surface of the particles, 30,31 stimuliresponsive polymers for on-demand therapeutic release kinetics, [32][33][34] small molecule-based therapeutics, [33][34][35] DNA-based therapeutics, 36 protein-based therapeutics, 35 and imaging agents 22 have been explored. Furthermore, the interaction of such systems with various cell types, 34,[36][37][38][39][40][41] their biodistribution in vivo, 42 and their functionality as carriers for dual therapeutic delivery to the cochlea 35,43 have demonstrated that multifunctional systems fabricated based on EHD co-jetting can be ideal carriers for targeted delivery in various applications. To date, the majority of these studies have been accomplished using microparticles, and while some have contained nanoparticles, 36,37,42 a systematic study into the fabrication of uniform, multifunctional nanoparticles using the EHD co-jetting system has not been reported.…”

mentioning

confidence: 99%

Engineering of nanoparticle size via electrohydrodynamic jetting

Rahmani

Ashraf

Hartmann

et al. 2016

Bioengineering & Transla Med

Self Cite

View full text Add to dashboard Cite

Engineering the physical properties of particles, especially their size, is an important parameter in the fabrication of successful carrier systems for the delivery of therapeutics. Here, various routes were explored for the fabrication of particles in the nanosize regime. It was demonstrated that the use of a charged species and/or solvent with high dielectric constant can influence the size and distribution of particles, with the charged species having a greater effect on the size of the particles and the solvent a greater effect on the distribution of the particles. In addition to the fabrication of nanoparticles, their fractionation into specific size ranges using centrifugation was also investigated. The in vitro particle uptake and intracellular transport of these nanoparticles was studied as a function of size and incubation period. The highest level of intralysosomal localization was observed for the smallest nanoparticle group (average of 174 nm), followed by the groups with increasing sizes (averages of 378 and 575 nm), most likely due to the faster endosomal uptake of smaller particles. In addition, the internalization of nanoparticle clusters and number of nanoparticles per cell increased with longer incubation periods. This work establishes a technological approach to compartmentalized nanoparticles with defined sizes. This is especially important as relatively subtle differences in size can modulate cell uptake and determine intercellular fate. Future work will need to address the role of specific targeting ligands on cellular uptake and intracellular transport of compartmentalized nanoparticles.

show abstract

“…MDM2 [ 77 ], cyclin-dependent kinase (CDK) 11 and casein kinase 2 (CK2) [ 78 ], c-Myc [ 79 ], survivin (also known as BIRC-5, an inhibitor of apoptosis protein) [ 80 , 81 ], mTORC 2 [ 82 ], Ataxia-telangiectasia mutated (ATM) protein [ 83 ], monopolar spindle 1 (MPS1, most commonly known TTK protein kinase) and cell division cycle protein 20 (CDC20) [ 84 ], Heparin-binding EGF-like growth factor (HB-EGF) [ 85 ], epidermal growth factor receptors (EGFR) [ 86 , 87 , 88 ], CXCR-4 [ 89 ], luciferase mRNA protein [ 90 ], and enhanced green fluorescent protein (eGFP) [ 91 ] are overexpressed in TNBC cells. Gene function studies showed that silencing any of these molecular factors using siRNA-mediated nanoparticles caused significant tumor growth suppression.…”

Section: Pre-clinical Activity Of Engineered Sirna-mediated Therapmentioning

confidence: 99%

Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

Hattab

Bakhtiar

2020

Pharmaceutics

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer. Owing to the absenteeism of hormonal receptors expressed at the cancerous breast cells, hormonal therapies and other medications targeting human epidermal growth factor receptor 2 (HER2) are ineffective in TNBC patients, making traditional chemotherapeutic agents the only current appropriate regimen. Patients’ predisposition to relapse and metastasis, chemotherapeutics’ cytotoxicity and resistance and poor prognosis of TNBC necessitates researchers to investigate different novel-targeted therapeutics. The role of small interfering RNA (siRNA) in silencing the genes/proteins that are aberrantly overexpressed in carcinoma cells showed great potential as part of TNBC therapeutic regimen. However, targeting specificity, siRNA stability, and delivery efficiency cause challenges in the progression of this application clinically. Nanotechnology was highlighted as a promising approach for encapsulating and transporting siRNA with high efficiency-low toxicity profile. Advances in preclinical and clinical studies utilizing engineered siRNA-loaded nanotherapeutics for treatment of TNBC were discussed. Specific and selective targeting of diverse signaling molecules/pathways at the level of tumor proliferation and cell cycle, tumor invasion and metastasis, angiogenesis and tumor microenvironment, and chemotherapeutics’ resistance demonstrated greater activity via integration of siRNA-complexed nanoparticles.

show abstract

CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Cited by 35 publications

References 35 publications

Nanoparticles for imaging and treatment of metastatic breast cancer

Nanoparticles for imaging and treatment of metastatic breast cancer

Engineering of nanoparticle size via electrohydrodynamic jetting

Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

Contact Info

Product

Resources

About